Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicament composition and package for fast reducing uric acid in blood and use of anserine for fast reducing uric acid in blood

A pharmaceutical composition, anserine technology, applied in the direction of drug combination, blood diseases, tripeptide components, etc.

Inactive Publication Date: 2009-04-29
LYTONE ENTERPRISE INC
View PDF1 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] However, no commercially available drug containing anserine for the treatment of gout has been reported to have the efficacy of rapidly reducing the level of uric acid in the blood of an individual

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament composition and package for fast reducing uric acid in blood and use of anserine for fast reducing uric acid in blood
  • Medicament composition and package for fast reducing uric acid in blood and use of anserine for fast reducing uric acid in blood
  • Medicament composition and package for fast reducing uric acid in blood and use of anserine for fast reducing uric acid in blood

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0029]Anserine (GL Biochem Ltd., Shanghai, China) and dextrin-maltose were filled into gelatin capsules (total weight 400 mg), and the capsules contained 50 mg anserine. Individuals suffering from gout who have high levels of uric acid in the blood take 3 capsules (total anserine 150 mg) twice a day and 5 capsules once on the same day (total anserine 250 mg), so the individual takes daily The total dose of anserine is 550mg. The uric acid content in the blood was monitored by UroSpeed ​​(a rapid serum-uric acid test strip, Apex Biotechnology Co., Inc., Hsinchu, Taiwan, ROC). The results are shown in Table 1 and further illustrated in figure 1 middle.

[0030] Table 1: Decrease in blood uric acid level 1 hour after oral administration of anserine

[0031]

[0032] as table 1 and figure 1 As shown, the reduction of uric acid levels in the blood ranged from 0.9 mg / dL to 1.5 mg / dL 1 hour after taking the capsules containing anserine. One hour after taking 150 mg of anserin...

example 2

[0034] In this oral administration test, 15 voluntary adult subjects (9 males and 6 females aged 28 to 53) suffering from chronic hyperuricemia were tested. The individual discontinued their normal medication for at least 3 days. The average uric acid level in the blood of the individual is greater than 9.3 mg / dL. The individuals were randomly divided into 5 groups, each group comprising 3 individuals, who took the following doses of anserine respectively: 50 mg, 100 mg, 150 mg, 200 mg and 250 mg. After 1 hour, the level of uric acid in the individual's blood was measured. The uric acid level in his blood was found to decrease by 1.1 mg / dL to 1.3 mg / dL. Among the 5 groups, the group taking 150 mg of anserine had the most significant reduction in blood uric acid levels. The results are shown in Table 2.

[0035] Table 2: Effects of 1 hour after oral administration of various doses of anserine on the uric acid content in blood

[0036]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition for rapidly reducing content of uric acid in individual blood, which comprises anserine in an amount larger than 50 mg to about 600 mg. the invention further relates to a package that comprises the pharmaceutical composition including anserine, and tags and / or inserts indicative of administering the composition to individual to offer anserine in an amount larger than 50 mg to about 600 mg per dosage. In addition, the invention relates to uses of anserine in the manufacturing of medicines for rapidly reducing content of uric acid in individual blood, wherein the medicine includes anserine in an amount larger than 50 mg to about 600 mg.

Description

technical field [0001] The present invention relates to the administration of anserine in an amount of greater than 50 mg to about 600 mg to rapidly reduce the level of uric acid in the blood of an individual. Background technique [0002] Uric acid is the final product of purine metabolism in the human body. The level of uric acid in the blood varies with the balance between the breakdown of purines and the rate of uric acid excretion. Hyperuricemia has been associated or considered identical to gout for several years, but uric acid has now been identified as a marker of a number of metabolic and hemodynamic abnormalities. High uric acid levels in the blood induce gout and are often associated with symptoms such as muscle cramps, localized swelling, inflammation, joint pain, muscle fatigue, pressure, and myocardial infarction. [0003] Various commercially available drugs have been used to treat gout, such as Benzbromarone (URINORM), Probenecid, Allopurinol, Bucolome, Cin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/06A61P7/00A61P19/06
Inventor 张天鸿陈禧莹王宜婕
Owner LYTONE ENTERPRISE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com